1. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017 Subject(s): Drug CostsDrug Industry -- economicsMedicaid -- economicsPharmaceutical Preparations -- classificationPharmaceutical Preparations -- economicsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesHumansUnited StatesUnited States. Department of Health and Human Services.Centers for Medicare & Medicaid Services (U.S.)
